Ipamorelin
Ipamorelin
The cleanest growth hormone secretagogue for muscle growth, fat loss, and sleep quality.
Medical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. Peptides discussed may be research compounds not approved for human use. Always consult a qualified healthcare provider before starting any peptide protocol. Read our full disclaimer →
Quick Reference
| Peptide Class | Growth Hormone Secretagogue (GHRP) |
| Half-Life | ~2 hours |
| Administration | Subcutaneous injection |
| Typical Dosage | 200–300 mcg, 2–3x daily |
| Cycle Length | 8–12 weeks |
| Evidence Level | Moderate Preclinical / Emerging Human |
| Legal Status | Research compound — not FDA-approved for human use |
| Approximate Cost | $30–$60 per vial |
How Ipamorelin Works
Selectively stimulates pituitary GH release via ghrelin receptor agonism without affecting cortisol or prolactin.
Ipamorelin is a selective growth hormone secretagogue that stimulates the pituitary gland to release growth hormone (GH) by acting as a ghrelin receptor agonist. Unlike older GHRPs (such as GHRP-6), Ipamorelin is highly selective — it stimulates GH release without significantly increasing cortisol, prolactin, or appetite. This selectivity makes it one of the cleanest GH secretagogues available. GH release triggers downstream production of IGF-1 in the liver, which mediates most of the anabolic, fat-mobilizing, and tissue-repair effects associated with growth hormone.
Evidence Base
Preclinical Evidence
Animal studies demonstrate dose-dependent increases in GH and IGF-1 levels, improvements in bone mineral density, and increases in lean body mass. Ipamorelin has shown particular promise in models of muscle wasting and age-related GH decline.
Human Evidence
Phase I/II clinical trials have demonstrated safe and effective GH stimulation in healthy volunteers and GH-deficient patients. Ipamorelin is frequently studied in combination with CJC-1295 to extend the duration of GH release.
Anecdotal Evidence
Widely regarded as the best entry-level GH secretagogue due to its clean side effect profile. Users consistently report improved sleep quality (particularly deep sleep), gradual improvements in body composition over 8–12 weeks, and enhanced recovery. The Ipamorelin/CJC-1295 combination is one of the most popular peptide protocols in the biohacking community.
Key PubMed References:
Safety Profile
Side Effects
Generally well-tolerated. Mild side effects include water retention (especially early in a cycle), mild fatigue, and injection-site reactions. Unlike GHRP-6, Ipamorelin does not cause significant hunger spikes or cortisol elevation.
Contraindications
Not recommended for individuals with active cancer due to IGF-1 elevation. Caution in diabetics due to potential insulin sensitivity effects. Not recommended during pregnancy.
PeptidePilot Assessment
Ipamorelin is PeptidePilot's top recommendation for users in the Goals & Performance and Hormones & Aging domains who prioritize lean muscle gain, fat loss, and sleep improvement. In our algorithm, it scores highest for users aged 35+ who report declining energy, suboptimal sleep, and body composition goals. It is almost always recommended as part of the Ipamorelin/CJC-1295 stack rather than as a standalone peptide.
📊 22% of PeptidePilot users with muscle growth and anti-aging goals receive Ipamorelin/CJC-1295 as their top match
Frequently Asked Questions
Explore More Peptides
The most researched healing peptide for joints, tendons, and gut tissue.
Systemic tissue repair and anti-inflammatory recovery for athletes and injury rehabilitation.
Extended-release GHRH analogue that amplifies and sustains growth hormone pulses.
The clinically established GHRH analogue with the longest safety record in anti-aging medicine.
The most clinically validated peptide for weight loss and metabolic health.
The next-generation dual-agonist delivering superior weight loss to Semaglutide in clinical trials.